Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
Sponsor: Evolv
Summary
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Participants are randomized to either the intervention group (8 capsules daily) or a control group receiving standardized healthy eating guidance from the American Diabetes Association. The study enrolls 98 male and female participants aged 18 and older with a BMI of 25-29.9 kg/m2. Primary endpoints include Hemoglobin A1c (HgbA1c) measured via bloodwork at Baseline, Week 6, and Week 12, as well as body weight and waist circumference measurements collected at Baseline, Week 4, Week 6, Week 8, and Week 12. Secondary endpoints capture participant perceptions of appetite suppression, weight loss, blood sugar, and overall well-being via self-reported questionnaires at the same time points.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
98
Start Date
2026-04-01
Completion Date
2026-07-01
Last Updated
2026-10-22
Healthy Volunteers
Yes
Interventions
Evolv GLP-1 Group
Participants take 8 capsules of Evolv GLP-1 daily (4 capsules in the morning and 4 capsules in the evening) for 12 weeks.
Control Group
Participants receive a standardized recommendation for healthy eating from the American Diabetes Association (https://diabetesfoodhub.org/blog/what-diabetes-plaand do not receive any study product.
Locations (1)
Citruslabs
Las Vegas, Nevada, United States